This document summarizes a study comparing the standard olanzapine tablet formulation to the oral dissolving olanzapine tablet (olimelt) in treating schizophrenia. Data was collected through surveys given to doctors at conferences and by sales representatives. The surveys focused on doctors' experiences with weight gain and patient preference between the two formulations. Statistical analysis using tools like the chi-square test was conducted on the survey responses to determine if preferences differed significantly between the formulations. The goal was to understand doctors' perceptions and develop national estimates of olimelt adoption over the standard tablet.